LATS1 and neoplasm: Tumor cells with LATS1/2 deficiency secreted nucleic acid-rich EVs to facilitate TLRs-Myd88/TRIF signaling and type I IFN production, which accelerated DC maturation, CD8+ T lymphocyte expansion, and tumor growth arrest (93).